HUP9900425A3 - Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes - Google Patents

Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes

Info

Publication number
HUP9900425A3
HUP9900425A3 HU9900425A HUP9900425A HUP9900425A3 HU P9900425 A3 HUP9900425 A3 HU P9900425A3 HU 9900425 A HU9900425 A HU 9900425A HU P9900425 A HUP9900425 A HU P9900425A HU P9900425 A3 HUP9900425 A3 HU P9900425A3
Authority
HU
Hungary
Prior art keywords
preventive
diagnostic
multiple sclerosis
therapeutic purposes
nucleotide fragments
Prior art date
Application number
HU9900425A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Publication of HUP9900425A2 publication Critical patent/HUP9900425A2/hu
Publication of HUP9900425A3 publication Critical patent/HUP9900425A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
HU9900425A 1995-08-03 1996-08-02 Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes HUP9900425A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9509643A FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Publications (2)

Publication Number Publication Date
HUP9900425A2 HUP9900425A2 (hu) 1999-05-28
HUP9900425A3 true HUP9900425A3 (en) 1999-11-29

Family

ID=9481811

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900425A HUP9900425A3 (en) 1995-08-03 1996-08-02 Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes

Country Status (19)

Country Link
US (4) US6001987A (enExample)
EP (2) EP1916304B1 (enExample)
JP (2) JP4444372B2 (enExample)
AT (2) ATE374252T1 (enExample)
AU (1) AU730080B2 (enExample)
BG (1) BG62977B1 (enExample)
BR (1) BR9606566A (enExample)
CA (1) CA2201282C (enExample)
CZ (1) CZ135797A3 (enExample)
DE (1) DE69637264T2 (enExample)
ES (2) ES2293645T3 (enExample)
FR (1) FR2737500B1 (enExample)
HU (1) HUP9900425A3 (enExample)
IS (1) IS4455A (enExample)
NO (1) NO971493L (enExample)
NZ (1) NZ316080A (enExample)
PL (1) PL319512A1 (enExample)
SK (1) SK56797A3 (enExample)
WO (1) WO1997006260A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP0938320B2 (en) * 1996-03-26 2014-06-18 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
WO1998014617A1 (en) * 1996-10-04 1998-04-09 Chronix Biomedical Diagnostic detection of nucleic acids
JP4226657B2 (ja) 1996-11-26 2009-02-18 ベーイーオー メリュー 診断、予防、及び治療のための、多発性硬化症に関連するウイルス性物質及びヌクレオチド断片
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
FR2762601B3 (fr) 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
FR2762600B1 (fr) * 1997-04-29 1999-11-05 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utlisations
US20040176314A1 (en) * 1997-07-07 2004-09-09 Bio Merieux Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
FR2765588A1 (fr) * 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
CA2298834C (fr) * 1997-07-07 2015-03-10 Bio Merieux Sequences retroviraux endogenes, associees a des maladies auto-immunes et/ou a des perturbations de la grossesse
JP2002511277A (ja) * 1998-04-08 2002-04-16 エムエス・リサーチ・アクティーゼルスカブ 多発性硬化症および他の脱髄性疾患の診断
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
FR2788784A1 (fr) * 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (en) * 1999-02-15 2000-08-23 Bio Merieux The LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
WO2001014564A2 (en) * 1999-08-20 2001-03-01 Curagen Corporation Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
DE10012875B4 (de) * 2000-03-16 2004-04-01 Infineon Technologies Ag Mobilfunkempfänger
EP1265989A2 (en) * 2000-03-21 2002-12-18 MS Research A/S An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
DE60239470D1 (de) * 2001-07-25 2011-04-28 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US8680065B2 (en) * 2008-09-11 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) * 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) * 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
JPH07508178A (ja) * 1992-05-18 1995-09-14 ジェネンテク，インコーポレイテッド レセプター活性化
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
ATE285475T1 (de) 1994-02-04 2005-01-15 Bio Merieux Msrv1 virus der mit multipler sklerose verbunden ist, seine nukleären bestandteile und verwendungen
US5691147A (en) * 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5710037A (en) * 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Also Published As

Publication number Publication date
US20070117189A1 (en) 2007-05-24
BR9606566A (pt) 1997-12-30
SK56797A3 (en) 1998-09-09
CZ135797A3 (cs) 1998-06-17
HUP9900425A2 (hu) 1999-05-28
US6579526B1 (en) 2003-06-17
CA2201282C (fr) 2013-04-02
AU730080B2 (en) 2001-02-22
JP4444372B2 (ja) 2010-03-31
ES2293645T3 (es) 2008-03-16
US20030186391A1 (en) 2003-10-02
EP1916304A2 (fr) 2008-04-30
FR2737500B1 (fr) 1997-08-29
JP2010047604A (ja) 2010-03-04
EP0789077B1 (fr) 2007-09-26
ES2379011T3 (es) 2012-04-19
EP1916304B1 (fr) 2012-01-18
EP1916304A3 (fr) 2008-05-07
ATE374252T1 (de) 2007-10-15
ATE541933T1 (de) 2012-02-15
DE69637264D1 (de) 2007-11-08
NO971493D0 (no) 1997-04-02
FR2737500A1 (fr) 1997-02-07
NO971493L (no) 1997-06-03
BG101355A (en) 1997-12-30
WO1997006260A1 (fr) 1997-02-20
PL319512A1 (en) 1997-08-18
BG62977B1 (bg) 2000-12-29
IS4455A (is) 1997-03-26
JPH11502416A (ja) 1999-03-02
DE69637264T2 (de) 2008-06-26
JP5143814B2 (ja) 2013-02-13
NZ316080A (en) 1999-04-29
US7932350B2 (en) 2011-04-26
AU6823296A (en) 1997-03-05
US6001987A (en) 1999-12-14
CA2201282A1 (fr) 1997-02-20
EP0789077A1 (fr) 1997-08-13

Similar Documents

Publication Publication Date Title
HUP9900425A3 (en) Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes
HUP9801207A3 (en) Therapeutic compositions for transfecting nucleic acids and use thereof
EP0710667B8 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
HUP9802130A3 (en) Heat treatment of carbon materials
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU2535795A (en) Puncture resistant material
GB9611729D0 (en) Novel material for flexible medical products
EP0709420A3 (en) Block copolymers of polyesters and polycarbonates and process for their preparation
ZA968796B (en) System for the heat treatment of metallic annealing material
IL124753A0 (en) Material for hair therapy
AU2832195A (en) Nucleic acid-binding oligomers for therapy and diagnosis
HUP9904173A3 (en) Pharmaceutical composition for treating viral diseases
EG20971A (en) Cutting refractory material
IL133739A (en) Shaped products or structures for medical or related purposes
EP0856580A4 (en) RECOMBINANT CONGLUTININ AND METHOD FOR THE PRODUCTION THEREOF
EP0846701A4 (en) RECOMBINANT CONGLUTININ AND PROCESS FOR ITS PRODUCTION
GB9622151D0 (en) Rubber-polyester composites including polystyrene-polyester copolymers
AU3300397A (en) Cyclin-c variants, and diagnostic and therapeutic uses thereof
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products
PL314166A1 (en) Flat fire-proofing material
ZA959051B (en) Recombinant dna
GB2303575B (en) Puncture resistant material
GB9325144D0 (en) Pangolin cricket armour
ZA963998B (en) 3,4-Disubstituted-phenylsulphonamides and their therapeutic use